These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Haematopoietic cell transplantation with and without sorafenib maintenance for patients with FLT3-ITD acute myeloid leukaemia in first complete remission. Brunner AM; Li S; Fathi AT; Wadleigh M; Ho VT; Collier K; Connolly C; Ballen KK; Cutler CS; Dey BR; El-Jawahri A; Nikiforow S; McAfee SL; Koreth J; Deangelo DJ; Alyea EP; Antin JH; Spitzer TR; Stone RM; Soiffer RJ; Chen YB Br J Haematol; 2016 Nov; 175(3):496-504. PubMed ID: 27434660 [TBL] [Abstract][Full Text] [Related]
6. Sorafenib maintenance after allogeneic haemopoietic stem-cell transplantation in patients with FLT3-ITD acute myeloid leukaemia: long-term follow-up of an open-label, multicentre, randomised, phase 3 trial. Xuan L; Wang Y; Yang K; Shao R; Huang F; Fan Z; Chi P; Xu Y; Xu N; Deng L; Li X; Liang X; Luo X; Shi P; Liu H; Wang Z; Jiang L; Lin R; Chen Y; Tu S; Zhang Y; Sun J; Huang X; Liu Q Lancet Haematol; 2023 Aug; 10(8):e600-e611. PubMed ID: 37414062 [TBL] [Abstract][Full Text] [Related]
7. Efficacy and feasibility of sorafenib as a maintenance agent after allogeneic hematopoietic stem cell transplantation for Fms-like tyrosine kinase 3-mutated acute myeloid leukemia. Battipaglia G; Ruggeri A; Massoud R; El Cheikh J; Jestin M; Antar A; Ahmed SO; Rasheed W; Shaheen M; Belhocine R; Brissot E; Dulery R; Eder S; Giannotti F; Isnard F; Lapusan S; Rubio MT; Vekhoff A; Aljurf M; Legrand O; Mohty M; Bazarbachi A Cancer; 2017 Aug; 123(15):2867-2874. PubMed ID: 28387928 [TBL] [Abstract][Full Text] [Related]
8. Effect of sorafenib on the outcomes of patients with FLT3-ITD acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation. Xuan L; Wang Y; Huang F; Jiang E; Deng L; Wu B; Fan Z; Liang X; Xu N; Ye J; Lin R; Yin C; Zhang Y; Sun J; Han M; Huang X; Liu Q Cancer; 2018 May; 124(9):1954-1963. PubMed ID: 29509276 [TBL] [Abstract][Full Text] [Related]
9. High rate of hematological responses to sorafenib in FLT3-ITD acute myeloid leukemia relapsed after allogeneic hematopoietic stem cell transplantation. De Freitas T; Marktel S; Piemontese S; Carrabba MG; Tresoldi C; Messina C; Lupo Stanghellini MT; Assanelli A; Corti C; Bernardi M; Peccatori J; Vago L; Ciceri F Eur J Haematol; 2016 Jun; 96(6):629-36. PubMed ID: 26260140 [TBL] [Abstract][Full Text] [Related]
10. [Improved clinical outcome of acute myeloid leukemia with FLT3-ITD mutation treated with sorafenib]. Gu B; Chen GH; Shen HJ; Ma X; Fu CC; Han Y; Tang XW; Miao M; Qiu HY; Sun AN; Wu DP Zhonghua Nei Ke Za Zhi; 2016 Apr; 55(4):293-7. PubMed ID: 27030618 [TBL] [Abstract][Full Text] [Related]
11. Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial. Xuan L; Wang Y; Huang F; Fan Z; Xu Y; Sun J; Xu N; Deng L; Li X; Liang X; Luo X; Shi P; Liu H; Wang Z; Jiang L; Yu C; Zhou X; Lin R; Chen Y; Tu S; Huang X; Liu Q Lancet Oncol; 2020 Sep; 21(9):1201-1212. PubMed ID: 32791048 [TBL] [Abstract][Full Text] [Related]
12. Synergistic effect of sorafenib and cGvHD in patients with high-risk FLT3-ITD+AML allows long-term disease control after allogeneic transplantation. Tschan-Plessl A; Halter JP; Heim D; Medinger M; Passweg JR; Gerull S Ann Hematol; 2015 Nov; 94(11):1899-905. PubMed ID: 26233683 [TBL] [Abstract][Full Text] [Related]
13. Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With Burchert A; Bug G; Fritz LV; Finke J; Stelljes M; Röllig C; Wollmer E; Wäsch R; Bornhäuser M; Berg T; Lang F; Ehninger G; Serve H; Zeiser R; Wagner EM; Kröger N; Wolschke C; Schleuning M; Götze KS; Schmid C; Crysandt M; Eßeling E; Wolf D; Wang Y; Böhm A; Thiede C; Haferlach T; Michel C; Bethge W; Wündisch T; Brandts C; Harnisch S; Wittenberg M; Hoeffkes HG; Rospleszcz S; Burchardt A; Neubauer A; Brugger M; Strauch K; Schade-Brittinger C; Metzelder SK J Clin Oncol; 2020 Sep; 38(26):2993-3002. PubMed ID: 32673171 [TBL] [Abstract][Full Text] [Related]
14. Treatment of FLT3-ITD-positive acute myeloid leukemia relapsing after allogeneic stem cell transplantation with sorafenib. Sharma M; Ravandi F; Bayraktar UD; Chiattone A; Bashir Q; Giralt S; Chen J; Qazilbash M; Kebriaei P; Konopleva M; Andreeff M; Cortes J; McCue D; Kantarjian H; Champlin RE; de Lima M Biol Blood Marrow Transplant; 2011 Dec; 17(12):1874-7. PubMed ID: 21767516 [TBL] [Abstract][Full Text] [Related]
15. [Efficacy and safety of gilteritinib-based combination therapy bridging allo-HSCT in relapsed or refractory acute myeloid leukemia patients with positive FLT3-ITD mutation]. Xu Y; Zhang J; Xue SL; Miao M; Wang Y; Chen SN; Qiu HY; Wu DP Zhonghua Xue Ye Xue Za Zhi; 2024 Apr; 45(4):357-363. PubMed ID: 38951063 [No Abstract] [Full Text] [Related]
16. Impact of genetic patterns on sorafenib efficacy in patients with FLT3-ITD acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation: a multi-center, cohort study. Shao R; Zhang Y; He J; Huang F; Fan Z; Yang K; Xu Y; Xu N; Luo Y; Deng L; Zhang X; Chen J; Han M; Li X; Yu S; Liu H; Liang X; Luo X; Shi P; Wang Z; Jiang L; Zhou X; Lin R; Chen Y; Tu S; Sun J; Wang Y; Liu Q; Xuan L Signal Transduct Target Ther; 2023 Sep; 8(1):348. PubMed ID: 37704613 [TBL] [Abstract][Full Text] [Related]
17. Efficacy and Feasibility of Sorafenib as a Maintenance Agent After Allogeneic Hematopoietic Stem Cell Transplantation for Fms-like Tyrosine Kinase 3 Mutated Acute Myeloid Leukemia: An Update. Battipaglia G; Massoud R; Ahmed SO; Legrand O; El Cheikh J; Youniss R; Aljurf M; Mohty M; Bazarbachi A Clin Lymphoma Myeloma Leuk; 2019 Aug; 19(8):506-508. PubMed ID: 31122828 [TBL] [Abstract][Full Text] [Related]
18. Allogeneic Transplantation in First Remission Improves Outcomes Irrespective of FLT3-ITD Allelic Ratio in FLT3-ITD-Positive Acute Myelogenous Leukemia. Oran B; Cortes J; Beitinjaneh A; Chen HC; de Lima M; Patel K; Ravandi F; Wang X; Brandt M; Andersson BS; Ciurea S; Santos FP; de Padua Silva L; Shpall EJ; Champlin RE; Kantarjian H; Borthakur G Biol Blood Marrow Transplant; 2016 Jul; 22(7):1218-1226. PubMed ID: 27058617 [TBL] [Abstract][Full Text] [Related]
19. [The efficacy of sorafenib to prevent relapse in patients with FLT3-ITD mutation positive acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation]. Zu YL; Zhang YL; Zhou J; Han LJ; Zhao HF; Gui RR; Hou YJ; Song YP Zhonghua Nei Ke Za Zhi; 2016 Aug; 55(8):634-6. PubMed ID: 27480560 [TBL] [Abstract][Full Text] [Related]
20. Outcome of FLT3-ITD-positive acute myeloid leukemia: impact of allogeneic stem cell transplantation and tyrosine kinase inhibitor treatment. Fleischmann M; Schnetzke U; Schrenk KG; Schmidt V; Sayer HG; Hilgendorf I; Hochhaus A; Scholl S J Cancer Res Clin Oncol; 2017 Feb; 143(2):337-345. PubMed ID: 27778197 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]